DF/HCC Breast & Gynecologic Cancer Symposium

On Friday, April 28, 2023 the Susan F. Smith Center for Women’s Cancers and the Breast and Gynecologic Programs in the DF/HCC will sponsor a day-long symposium to highlight breast and gynecologic cancer research at Harvard.

We invite all DF/HCC researchers who are doing work in breast and gynecologic cancers, including fellows, post-docs, and junior faculty to attend and to submit abstracts. 


Register/Submit an Abstract

2023 Agenda

April 28, 2023

Joseph B. Martin Conference Center 

Harvard Medical School 
77 Avenue Louis Pasteur
Boston MA, 02115

7:15 am  Sign-In, Continental Breakfast, Poster Set-Up    
8:00 am  

Welcome/Purpose of Symposium

Susan F. Smith Center Leaders
8:10 am

“STICs make tumors nervous”
Ronny Drapkin, M.D., Ph.D.
Franklin Payne Chair in Gynecologic Oncology
Director, Penn Ovarian Cancer Research Center
Director, Gynecologic Cancer Research, Basser Center for BRCA
Assistant Dean, Department of Defense Ovarian Cancer Academy
(35-40 min talk, 10 mins questions)

9:00 am 

SESSION I: Genomics
Chair: Gerburg Wulf

9:00 – 9:45 am

3 oral presentations (12 mins each); 3 mins questions

Abstract #25

Dominik Glodzik: Timing onset of homologous recombination deficiency before cancer diagnosis in BRCA1/2 mutation carriers

Abstract #26

Po-Han Lin: Genomics and transcriptomics landscape of early pathogenesis of the BRCA1/2-associated breast cancer

Abstract #27

Stefania Morganti: Clonal hematopoiesis of indeterminate potential (CHIP) after (neo)adjuvant chemotherapy (CT) versus endocrine therapy (ET) for early breast cancer (eBC): the CIRCE-eBC prospective cohort study

9:45 am

9:45 am – 10:30 am – Open Posters

10:30 am 

SESSION II: Risk, Prevention & Disparities/Clinical

Chair: Sara Tolaney
10:30 – 11:30 am 4 oral presentations (12 mins each); 3 mins questions 
Abstract #5

Cheng Peng: Regular Aspirin Use and Long-term Breast Cancer Survival

Abstract #19 Joseph Dottino: Who is first in line? Trends in use of poly-ADP ribose polymerase inhibitors (PARPi) among commercially insured women with ovarian cancer
Abstract #22 Filipa Lynce: A phase Ib study of sapacitabine (sapa) and olaparib (ola) in patients (pts) with BRCA1/2-mutated (BRCA1/2m) metastatic breast cancer (MBC)
Abstract #31

MacLean Sellars: Personalized targeted circulating tumor DNA (ctDNA) to monitor response to combined neoantigen vaccine and immune checkpoint blockade in ovarian cancer

11:30 am 

“Regulatory Strategies to Address Unmet Need in Breast Cancer”
Tatiana M. Prowell, M.D.
Breast Cancer Scientific Liaison, U.S. Food and Drug Administration
Associate Professor of Oncology, Breast Cancer Program, Johns Hopkins           
University School of Medicine
(35-40 min talk, 10 mins questions)

12:15 pm

Lunch and Open Posters
12:15 – 1:15pm

 1:15 pm  

SESSION III: Drug Resistance/Animal Models
Chair: Patricia Donahoe

1:15 – 2:15 pm 4 oral presentations (12 mins each); 3 mins questions
Abstract #43 Joshua Rivera: Single Cell Transcriptomics Reveals Putative Tumor Promoting Subpopulation in Brca1 Mutant Breast Cancer Mouse Model
Abstract #45

Alexandre da Costa: The USP1 inhibitor I-138 kills BRCA1-deficient tumor cells and overcomes PARP inhibitor resistance

Abstract #57 

Bogang Wu: Systematic identification of pathways associated with antibody drug conjugate sensitivity in breast cancer

Abstract #59 Oladapo Yeku: Antibody Drug Conjugates against MUC16 for Ovarian Cancer
2:15-2:30   15-Minute Break
2:30 pm   SESSION IV: Tumor Microenvironment/Immunology
Chair: Jean Zhao
2:30 – 3:30 pm

 4 oral presentations (12 mins each); 3 mins questions

Abstract #32

Triet Bui: The Single-Cell Trajectory of Immune Escape During DCIS-IDC Progression

Abstract #34  Maeva Chauvin: The role of cancer-associated mesothelial cells in the ovarian tumor microenvironment
Abstract #35

Jenny Hogstrom: Modeling drug resistance in ER+ breast cancer using patient-derived organoid cultures and cancer-associated fibroblasts

Abstract #62

Jeffrey Patterson-Fortin: Polymerase θ inhibition activates the cGAS-STING pathway in BRCA1-deficient breast cancer

3:30 pm

Announcement of Awards and Adjourn